Skip to main content
Evidence Snapshot

5'-AMP-activated protein kinase catalytic subunit alpha-2

CHEMBL2116 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:13Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2116
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats 5'-AMP-activated protein kinase catalytic subunit alpha-2 as ChEMBL target CHEMBL2116, mapped to UniProt P54646. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
5'-AMP-activated protein kinase catalytic subunit alpha-2
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL2116
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P54646
5'-AMP-activated protein kinase catalytic subunit alpha-2
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why 5'-AMP-activated protein kinase catalytic subunit alpha-2 matters

As of 2026-09-14

5'-AMP-activated protein kinase catalytic subunit alpha-2 is reviewed as 5'-AMP-activated protein kinase catalytic subunit alpha-2 (UniProt P54646); the current evidence base includes 7 approved drugs, 1408 compounds, and 180 assays, with lead potency reaching pChEMBL 9.1.

Protein context
5'-AMP-activated protein kinase catalytic subunit alpha-2

5'-AMP-activated protein kinase catalytic subunit alpha-2 Sequence length is 552 aa.

Review this target as 5'-AMP-activated protein kinase catalytic subunit alpha-2, mapped to UniProt P54646. Sequence length is 552 aa.

Protein source · UniProt accession via ChEMBL component mapping
UniProt P54646 Protein
Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 7 approved drugs, 1408 compounds, and 180 assays for this target. The dominant activity type is EC50. CHEMBL3969654 is the current potency anchor at pChEMBL 9.1.

Use CHEMBL3969654 as the tractability anchor when discussing potency (pChEMBL 9.1).

Activity source · ChEMBL 36 via Core Engine
7 approved pChEMBL 9.1
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why 5'-AMP-activated protein kinase catalytic subunit alpha-2 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P54646, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

1408
Total Compounds
180
Total Assays
7
Approved Drugs
IC50: 35.0, KI: 2.0, EC50: 519.0, KD: 122.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL3969654
 9.1 EC50 —
No preferred name
CHEMBL273453
 8.9 EC50 Clinical
No preferred name
CHEMBL3955171
 8.7 EC50 —
No preferred name
CHEMBL3970694
 8.7 EC50 —
No preferred name
CHEMBL3895006
 8.6 EC50 —

Approved Drugs

Structure Compound First Approval
MIDOSTAURIN
CHEMBL608533
 2017
NINTEDANIB
CHEMBL502835
 2014
SUNITINIB
CHEMBL535
 2006
EBASTINE
CHEMBL305660
 1990
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:13Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2116